StockNews.AI
RVPH
StockNews.AI
142 days

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

1. RVPH presents data from the Phase 3 RECOVER study on brilaroxazine. 2. The presentation will occur at the SIRS Congress from March 29 to April 2. 3. Brilaroxazine targets schizophrenia, showing promise in addressing unmet medical needs. 4. Reviva holds patents for brilaroxazine and RP1208 in multiple jurisdictions. 5. The company's focus includes CNS, inflammatory, and cardiometabolic diseases.

4m saved
Insight
Article

FAQ

Why Bullish?

The presentation of positive study data can enhance investor confidence and stock price, similar to prior biotech successes following positive study results.

How important is it?

The upcoming data presentation is crucial for RVPH's market perception and could influence stock performance significantly.

Why Short Term?

Immediate reactions are expected during the conference, impacting RVPH's stock price in the short-term, as momentum builds around study results.

Related Companies

VRTXINONVS
March 30, 2025 11:30 ET  | Source: Reviva Pharmaceuticals CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S. Details for the oral presentation can be found below: Title: Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants Session: Pharmaceutical Pipeline Date and Time: Sunday, March 30th from 10:30 AM – 12:00 PM ET CST Presenter: Dr. Laxminarayan Bhat, Founder & CEO, Reviva Pharmaceuticals Abstracts and additional details can be found at the SIRS 2025 website. About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. Corporate Contact:Reviva Pharmaceuticals Holdings, Inc.Laxminarayan Bhat, PhDwww.revivapharma.com Investor Relations Contact:LifeSci Advisors, LLCBruce Macklebmackle@lifesciadvisors.com

Related News